Azafaros
5 known investors
Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism. Its lead candidate is being evaluated in a Phase 3 study for treating patients with GM1/GM2 gangliosidoses and related rare lysosomal storage disorders.
BiotechMedical Devices